{"name":"Cerebral Therapeutics LLC","slug":"cerebral-therapeutics-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxNUEd6bmFmQWExTlVkNEhNcXFlLVEyem84bVZKT1ZxdXFlbDNuN3FhU1BzWE9hWU5Ja19PZEw3ZDJIWlV0S1NHRFBCVlJSV1NWODJ0M3Zhb2tQUWJpYUVnYk5qS05YYlZ2T2ExNjgwdmRyNkMwNndzbmpFQ1VieWp4YTRGSEFkek9xNjhrUFdWR0ctNE9UdGt1MjF2dTcxa2tQV3ZLTnJ3aWZhclNiTjRwZVBxX0g3NlVaVUFaT0NlOVlrTG1QcFFaMmx3NkFiSlVKWFJiY3FTX1RVLVg1ZHJVSFVYNU1MSS1pc01NOFE2NVZhZHhVVDUxZTVKWmU0SEVWVG9hRW10T3lZZVhLQ1kzODR2T0Z4QncyaGFyVWlNTzdzcWpMMTRUbU9kUU1xVm56VnE0cGVxNzRLQlA5aGdJYmoxbnNUQ3BmWXRJ?oc=5","date":"2026-04-07","type":"regulatory","source":"Barchart.com","summary":"Epilepsy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharma, SK Biopharma - Barc","headline":"Epilepsy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Aques","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBOdmVrdXhpenEwekdvbjdVU3BMX25BNHE5NERjbUFtRGtlUWVwZklQLXNHSklCMFRfb0VhQUtRdVRYUmlUNk5oS3F0LUdLbjBLV211bEUxMV85VXFNdDl2UFBDX05fRkplNGl5elYzZXFUM3RxN1Atdw?oc=5","date":"2026-01-15","type":"pipeline","source":"neurologytoday.aan.com","summary":"AAN Releases First Guidelines for Managing Functional Seizures - neurologytoday.aan.com","headline":"AAN Releases First Guidelines for Managing Functional Seizures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9vNllnQ19pRmhEZXB2NTVKYVBkemxJaWh3WjVOeWV4MVBRY05Bb1U5cGxJNk9IM3VCU081SE5fcXlCT0RQTktiQ01aVVZjbWh6NGxBbWFzQU5wT3NjeEdRTFFjWGYxUGhWWkZUaURNZjNqSjhPZTZpeA?oc=5","date":"2026-01-02","type":"pipeline","source":"neurologytoday.aan.com","summary":"Fathers' Use of Valproate Raises Risk of Neurodevelopmental Disorders in Offspring - neurologytoday.aan.com","headline":"Fathers' Use of Valproate Raises Risk of Neurodevelopmental Disorders in Offspring","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNenJOQkY3Mk5hWVVnRFVKTVZ6T2tqWDJtOHhfbThzRlEweHlyOUFQX2hwVjlOcjVtUjNKeDhBV0pvMk5nSUtoWDk1dTZxZkV4dmZNaVVsZUg2ZmViZXI2QTdxYkdtSmlaRDNvblNvRlZaRnF6SzZPU0ZXazR2d3BWT3JseDdjS1Z1YmE1ZXhCWXN5U2cw?oc=5","date":"2025-12-09","type":"pipeline","source":"Yahoo Finance","summary":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Yahoo Finance","headline":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9JWkRkeFlSN3VjVk9ndlpHeGVxTDdBVU1aOTIxS09VMno0QzBEOUVNd2otN3czbjNBVG1TaGF2Y3R2OS1LY1l5Sk9PUU4zWHlGNmlYZzBQSUpPdjZyMUdTTEZqRTdBclBpR05XVFVHam9LdmZxVnBXaEM4V2tzQQ?oc=5","date":"2025-08-11","type":"pipeline","source":"Fierce Pharma","summary":"UPDATED: Most expensive drugs in the US in 2025 - Fierce Pharma","headline":"UPDATED: Most expensive drugs in the US in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQLXRVRjFtRS1JN1VXV011a085Vjh3RTh3Xy12ZkFrWkc2VFVwTXNpNzZMNUpLaFBTOV9mUE8xamFtcGxBdHEwSlNxRmtUeXM1cEFhc2txYXR1akVIODFHalBPUGktVTJDRVhxcGdrTllObFMxaTFEaW14dHpyU1JMVzhiWmYtTDhlUXp2U1hsSVNJeDdsUHM1UVIzeUFYbk1SalJ4YlZpdkpSMVJpc2I0?oc=5","date":"2025-08-08","type":"regulatory","source":"Fierce Pharma","summary":"FDA restricts bluebird bio gene therapy Skysona after blood cancer reports - Fierce Pharma","headline":"FDA restricts bluebird bio gene therapy Skysona after blood cancer reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxNSm1rNWlLNmo3OURRbkVFY1djc0paTWs3ajVWVkVxenhRbGtlQlFKT3NkeEpHSmVhU2IxRHU2aENMWUhoWUdFTHRyODRuQkU1RzBYN0NHMzkwdXFwVlZmVllUSmZ4eDZuTnR6WHpxUW9hS05RMzZteUF6eUtYUDRua0ItTWpNVTNDN3JGQzdNTVJfYndIaW1RMlVacWtoemhTNm9YXzdyVWdBd2gxMGNDampZb0ExQjljcFR2Uk92OTVtLWtKZU96RlE0RUUzaVVXM29xRlpEcW9idU1ac2FrbWN2M0dvYmhSS0ZNSjdyQ3lmaXZsVjgtcnBHTUZpRkphMGN0QkZhc3J5clg4WEtPN2VwOXlZckJEU0d2WHp6bnZWMkJUYi1uRkI3ZGJPY2tLenNDYTNHZmphVVdXT25JYXdsZElUVHR3Mi12c2VVNS0?oc=5","date":"2025-02-06","type":"pipeline","source":"GlobeNewswire","summary":"Drug Delivery Across Blood Brain Barrier (BBB) Market Eyes - GlobeNewswire","headline":"Drug Delivery Across Blood Brain Barrier (BBB) Market Eyes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPY2t1WXAtVEdTcnA2d1N0cWZ5WThMN2tuZnhlbHM2RHVNc0lZVkhzS09hM3hvM0g5WFZvVkFVV0l1V0NZMVhfNEplQmtFb19tNmlSeWUyVjFOeUhvYkFYN1diak84QVc3eVAxbFdUZWczeXpZZTBOTWxTTHR6MVZsMXBwYjZjaWxNRTR1UA?oc=5","date":"2024-01-24","type":"pipeline","source":"Wyss Institute at Harvard","summary":"Brain Shuttle Research Sponsorship & Licensing - Wyss Institute at Harvard","headline":"Brain Shuttle Research Sponsorship & Licensing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQZVBLWDNSM1lQWUtIbFBxX3Z0VURQbjBIa0RVXzZWZkxWOWUta2NPZE1MRUdMZXpqM2Z4Qjl4cHJFUUhYWjdTcUJmYUJTeWFWdmxiVl9OcXR6dEpPZXVWWWNmQk5CRC1SVGhfS19nTlI2bl9qWGtGR3JxUlp4aHBtc1lwX0dDdjY2NDc1MnZ6Y0VOVnZSalNZRV8yUjJ5SVVBWVY1NE02OURLLXlKaUxkMkNreVozSjZ0QmdvLTJtOUtfcnhoMDZ0Yg?oc=5","date":"2023-11-08","type":"pipeline","source":"Healio","summary":"XEN1101 significantly reduced monthly seizures for adults with focal-onset epilepsy - Healio","headline":"XEN1101 significantly reduced monthly seizures for adults with focal-onset epilepsy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQS2VHSU42M3B1RXQ4bUJnT2xfRFdxcTFULTJYZndGMTlQT2dBaUp2R0daMzZXMHFPZU9vWDQ0a0dTME9OVmlQVkp2bTFKZ04xVng1TUNVbGY4MllHbURIcTNiV3hNZlpkR0E1U2FEZVZOaXFqbGYxN2h5RUpaOWp1MmszTFk3bW1tTXlCNnB1RVgyNncwY1Npend1ZlNrSS00QmhWcWFUZ1ppd1gzUk4tRW9LQzNpVzRxVmdpNzdObWhobnB5WE1KNmhiNGlRVkFCSEl2VHREVFd4SDBqQnBKSU5oMUVZTUZHQjNseVNmTndfUndUZUw4?oc=5","date":"2023-04-11","type":"pipeline","source":"prnewswire.com","summary":"DelveInsight Evaluates a Robust Epilepsy Pipeline as 70+ Influential Pharma Players to Set Foot in the Domain - prnewswire.com","headline":"DelveInsight Evaluates a Robust Epilepsy Pipeline as 70+ Influential Pharma Players to Set Foot in the Domain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBxYXZpWVV5bUMxSUg2UkdpeG9mZ1haT3dHY3JFOHJRMGU3cHJwMThKWDNXRmphSmJPYk1mMzMwNFF5RC1SVHc3MnYxY18xZU1DMGNyRGlkbTBlblVaTFpnTXVDZXpqeWlsY1E?oc=5","date":"2022-10-21","type":"trial","source":"Wiley Online Library","summary":"A randomized phase 2b efficacy study in patients with seizure episodes with a predictable pattern using Staccato® alprazolam for rapid seizure termination - Wiley Online Library","headline":"A randomized phase 2b efficacy study in patients with seizure episodes with a predictable pattern using Staccato® alpraz","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPOFRVTTd5emdKR2h3NU5YdFhPVTdfN0NMa2h0V29fUHpMN0o3SWYwZDJLSWp6QkRFOFdaNk5rM2JfSmRCbk45X2FEUUJXTXc1MEpPZ3lXRGJBZTBObVRDLXZ5M29DOTBnYWdLbkRabnRVaTBmZnI5Mm4tTzgyRjBTTHd4TFRDVC1mSFlVQnJXNDlJT3dWdzRTRFlSdEI5OG5ZVlMzWHYxcGVRRnJ6bW5TX0l5YllZYzVOU0VDVXk3eXkwdw?oc=5","date":"2022-06-28","type":"pipeline","source":"businesswire.com","summary":"Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing - businesswire.com","headline":"Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}